Ironwood Pharms

IRWD NASDAQ
11.27
-0.29
-2.51%
After Hours: 11.27 0 0.00% 16:41 06/20 EDT
Open
11.75
Prev Close
11.56
High
11.84
Low
11.25
Volume
951.89K
Avg Vol (3M)
1.37M
52 Week High
17.74
52 Week Low
7.59
% Turnover
0.61%
Market Cap
1.75B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Ironwood Pharms IRWD stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
MORE >

Recently

Name
Price
%Change